Chemistry:Bentracimab
From HandWiki
Short description: Medication
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Human |
| Target | Ticagrelor, AR-C124910XX (the active metabolite)[1] |
| Clinical data | |
| Other names | PB2452, MEDI2452 |
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2095H3240N560O674S12 |
| Molar mass | 47440.93 g·mol−1 |
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3][4] It is not commercially available.
See also
- Other reversal agents for antithrombotic drugs
References
- ↑ "Specialist Pharmacy Service: Bentracimab". National Health Service. 10 January 2021. https://www.sps.nhs.uk/medicines/bentracimab/.
- ↑ "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". 2021-01-29. https://cardiovascularnews.com/first-eu-patients-enrolled-in-reverse-it-trial-of-bentracimab-for-reversal-of-antiplatelet-effects-of-ticagrelor/.
- ↑ Clinical trial number NCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" at ClinicalTrials.gov
- ↑ "Ticagrelor use and practice patterns among Canadian cardiac surgeons". Journal of Cardiac Surgery 36 (8): 2793–2801. August 2021. doi:10.1111/jocs.15636. PMID 34028081.
 |  |
